Current HLA testing recommendations to support HCT

Hum Immunol. 2022 Oct;83(10):665-673. doi: 10.1016/j.humimm.2022.04.008. Epub 2022 Jul 4.

Abstract

Supporting allogeneic hematopoietic cell transplantation (HCT) is an integral function of the clinical HLA laboratory, which provides HLA testing for recipients and donors. However, the timing, scope, and methods of the HLA tests vary significantly in the field. This summary provides a comprehensive and practical HLA testing approach to maximize the efficiency of the donor search process, minimize donor-specific HLA antibody (DSA) associated risks, enable optimal donor selections, and support HCT multidisciplinary teams. This is not a comprehensive donor selection guide, but pertinent donor selection considerations and publicly available online selection tools are highlighted. In the absence of healthy HLA identical siblings, younger 8/8 (HLA-A, -B, -C, -DRB1) HLA-matched unrelated donors remain the most favorable choice for HCT. Emerging practices in preparative regimens and graft versus host disease (GvHD) prophylaxis as well as building evidence of the importance of other HLA (e.g., HLA-DPB1 allele and functional matching) and non-HLA (e.g., age, CMV, and KIR) donor attributes urge the transplant centers and the HLA laboratories to construct a comprehensive approach for the routine histocompatibility testing.

Keywords: Donor-specific HLA antibody; HLA Testing; Hematopoietic Cell Transplant; Unrelated-donor; Virtual crossmatch.

Publication types

  • Review

MeSH terms

  • Donor Selection
  • Graft vs Host Disease* / prevention & control
  • Hematopoietic Stem Cell Transplantation*
  • Histocompatibility Testing
  • Humans
  • Siblings
  • Unrelated Donors